Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

Authors:

Abstract
No abstract available
Funding Information
  • Merck Sharp and Dohme United Kingdom
  • Eisai Canada

This publication has 26 references indexed in Scilit: